title: [Primary lateral sclerosis and lung adenocarcinoma].
abstract: BACKGROUND
  Lung cancer is frequently associated with paraneoplastic syndromes, sometimes uncommon, among which motor neurone disease is sometimes described, including primary lateral sclerosis, a disorder characterized by slowly progressive cortico-spinal dysfunction due to the degeneration of the upper motor neurone.
  
  
  METHODS
  We report a case of primary lateral sclerosis developing in a young woman 9 months after the diagnosis of metastatic adenocarcinoma of the lung. Our patient showed a spastic quadriparesis, dysarthria and bulbar symptoms without amyotrophy nor fasciculation. The electromyogram showed isolated upper motor neurone involvement. Cerebral and medullary imaging and CSF analysis showed no abnormality and onconeuronal antibodies were negative. The neurological symptoms and the cancer deteriorated simultaneously and our patient died 6 months after the onset of neurological symptoms.
  
  
  CONCLUSIONS
  Motor neurone involvement is rare but some case reports describe an association with neoplasia without formal confirmation of a paraneoplastic syndrome. Our case is the first report of primary lateral sclerosis in a young woman diagnosed during the treatment of lung adenocarcinoma.
authors.affiliation: Service de pneumologie, hôpital de Brabois, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France. laura.martinez.1@hotmail.fr
authors.forename: L
authors.initials: L
authors.lastname: Martinez
authors.forename: R
authors.initials: R
authors.lastname: Lamaze
authors.forename: C
authors.initials: C
authors.lastname: Clément-Duchêne
mesh_terms: D000230:Adenocarcinoma / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D015984:Causality; D003937:Diagnosis, Differential; D004401:Dysarthria / Q000209:etiology; D004576:Electromyography; D017809:Fatal Outcome; D005260:Female; D000077156:Gefitinib; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D008207:Lymphatic Metastasis; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000150:complications* / Q000175:diagnosis; D009046:Motor Neurons / Q000502:physiology; D064847:Multimodal Imaging; D020361:Paraneoplastic Syndromes, Nervous System / Q000175:diagnosis; D000068437:Pemetrexed; D016066:Pleural Effusion, Malignant / Q000209:etiology; D049268:Positron-Emission Tomography; D011782:Quadriplegia / Q000209:etiology; D011799:Quinazolines / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
chemical_list: D000305:Adrenal Cortex Hormones; D005971:Glutamates; D011799:Quinazolines; D000068437:Pemetrexed; D006147:Guanine; D016190:Carboplatin; D000077156:Gefitinib